Navigation Links
Sygnis Pharma AG announces date for presentation of clinical,results

HEIDELBERG, Germany, 11 July 2007 – On 23 July SYGNIS Pharma AG will present the results of the clinical phase IIa study for AX200 (AXIS-study).

AX200, a compound for the treatment of stroke, is the most advanced drug candidate in SYGNIS’ product pipeline. The primary aim of the study is to show safety and tolerability of AX200 in acute stroke patients. The results of the AXIS-study are expected to provide information for the further clinical development of AX200.

Furthermore, the company announces that this year’s Annual General Meeting will take place on 28 November 2007 in Eppelheim.

About SYGNIS Pharma

SYGNIS Pharma AG, with head offices in Heidelberg, is a specialist pharmaceutical company listed on the Prime Standard of the German stock exchange. The company is focusing on the research, development and marketing of innovative therapies for the treatment of neurodegenerative diseases. These include stroke, Amyotrophic Lateral Sclerosis (ALS), Huntington's Disease or neurological disorders resulting from injury, such as trauma of the brain or spinal cord. All these disorders are characterised by the fact that, as the disease progresses, nerve cells die off. Although there is a great medical demand, there are currently no or only inadequate treatment options available.

In its drug development, the company has taken a completely novel approach: it develops compounds that protect nerve cells in the acute phase of the disease, and beyond that, also stimulate the regeneration of the damaged nervous system.

For more information, please contact:

Dr. Franz-Werner Haas Vice President Operations +49 (0) 6221 454 812 franz-werner.haas@sygnis.de

### Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as f
'"/>




Page: 1 2

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
11. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Sygnis Pharma announces date for presentation clinical results
(Date:9/2/2014)... , Sept. 2, 2014  Boston Scientific Corporation (NYSE: ... announced agreement to purchase the Interventional business of ... Boston Scientific to offer physicians and healthcare systems ... challenging vascular conditions. The addition of ... technologies supports the Boston Scientific strategy to provide ...
(Date:9/2/2014)... DIEGO , Sept. 2, 2014  Volcano ... company focused on improving patient and economic outcomes ... innovative minimally invasive coronary and peripheral visualization, physiology ... be participating in the Morgan Stanley Healthcare conference ... by Scott Huennekens , president and chief ...
(Date:9/2/2014)... , Sept. 2, 2014  Arena Pharmaceuticals, Inc. (NASDAQ: ... Food and Drug Administration (FDA) has granted orphan drug ... hypertension. "The FDA Office of Orphan ... from sponsors to identify and designate drug candidates that ... evaluation and development of such products," said Craig ...
Breaking Medicine Technology:Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG 2Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG 3Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG 4Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG 5Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension 2Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension 3Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension 4
... SUNNYVALE, Calif., July 7, 2011 Cepheid (Nasdaq: ... for its 2011 second quarter ended June 30, 2011, on ... The company will host a management presentation at ... discuss the results.  To access the live webcast, please visit ...
... just three weeks after hearing oral argument, the First District ... judgment against Johnson & Johnson (NYSE: JNJ ) ... death case involving their Duragesic® fentanyl pain patch. ... in DiCosolo v. ALZA Corp, et al ., obtained ...
Cached Medicine Technology:Cepheid Schedules 2011 Second Quarter Financial Results Announcement and Webcast 2Heygood, Orr & Pearson: Court of Appeals Affirms $16.56 Million Judgment in Defective Fentanyl Patch Case 2Heygood, Orr & Pearson: Court of Appeals Affirms $16.56 Million Judgment in Defective Fentanyl Patch Case 3
(Date:9/2/2014)... (PRWEB) September 02, 2014 Anti-aging ... products and services such as anti-wrinkle treatments and ... based treatments, and breast augmentation becoming much sought ... by U.S.-based market intelligence firm Transparency Market Research, ... products will grow to USD 191.7 billion by ...
(Date:9/2/2014)... CITY, GA (PRWEB) September 02, 2014 Last ... whole new level with the launch of a luxurious line ... to announce that the SEA ISLAND COTTON Socks are joining ... compression level, giving more people the comfort of natural cotton ... COTTON Socks, they are surprised to find socks as soft ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 Alliance Strategies ... and multi-channel email marketing is pleased to announce it ... Firearms & Freedom as well as ... represent more than one million concerned Americans who can ... , “We are honored to continue providing our ...
(Date:9/2/2014)... What happens when you are hospitalized, but your ... arrive at the office for follow-up care, but ... about your hospital stay? Missing or incomplete ... (PCPs) can contribute to poor experiences and lead ... study shows that implementing guidelines can improve hospitals, ...
(Date:9/2/2014)... health risks, including heart disease and diabetes, but University ... mitigate one often-overlooked risk: not buckling up in the ... Jacobson, a professor of computer science and of mathematics, ... a decrease in seatbelt usage. However, these effects can ... "Primary seatbelt laws lead to increased use of seatbelts," ...
Breaking Medicine News(10 mins):Health News:Global Anti-aging Market Research Report 2018 by Transparency Market Research 2Health News:Global Anti-aging Market Research Report 2018 by Transparency Market Research 3Health News:SIGVARIS’ Luxury Line of Compression Socks, SEA ISLAND COTTON, Now Available in Stronger Compression Level 2Health News:ASG Continues to Bring New Lists to Market 2Health News:ASG Continues to Bring New Lists to Market 3Health News:Can data motivate hospital leaders to improve care transitions? 2Health News:Seatbelt laws encourage obese drivers to buckle up 2
... bit relaxed now. Genosis Inc, a US firm, has developed ... test has his and hers components a screening test ... the concentration of motile sperm, and a test for women ... ,The availability of the two-in-one test helps drive ...
... Depressed? Consider marriage as an option please, a pair of ... happier you could be after marriage . And never mind ... to benefit, claim Adrianne Frech, a sociology graduate student at ... ,They looked at a sample of 3,066 men and women ...
... WASHINGTON, D.C. A first-of-its-kind study presented at the 54th ... molecular imaging and nuclear medicine professionals , declares that ... tumor patients' response to treatment is a powerful predictor ... to the possibility that brain tumor patients may live ...
... of Preferred Provider Organizations (AAPPO) is launching a new ... care to those patients diagnosed with diabetes as ... An industry leader, AAPPO today kicked off its new ... take Action, Champion better care, and empower their patients ...
... announced today that HHS has awarded a contract for $500 ... manufacture and deliver 20 million doses of a next generation ... would be recommended in the event of a smallpox outbreak ... immune systems. The full supply of the vaccine will be ...
... Mental Health Services Administration (SAMHSA) today announced that ... three years to the state of Iowa ... The first year award is $400,000. This grant ... intervention and treatment services for youth suicide prevention ...
Cached Medicine News:Health News:Fertility Test at Home Possible With a New Kit 2Health News:Marriage Could Lift One Out of Depression, New Study 2Health News:Brain Tumor Patients Survival Depends on Predicting Treatment Responses Earlier 2Health News:AAPPO Launches ACT on Diabetes Initiative to Promote Improved Diabetes Care 2Health News:HHS Buys Next Generation Smallpox Vaccine 2Health News:HHS Buys Next Generation Smallpox Vaccine 3Health News:Iowa to Receive Grant Funding for Youth Suicide Prevention, Early Intervention 2
... Minimize Patient Trauma and Increase Staff Protection ... (10 Fr, 12 Fr, 14 Fr, 16 ... Suction Catheters with Contro-Vac Valves and DeLee ... potential for inflammation,during suctioning. Each catheter utilizes ...
SAFE-T-VAC Coil Packed Suction Catheters Kits, Sterile without Solution...
Sterile, Coil Packed Suction Catheter Mini Tray with (2) Walleted SAFESKIN PURPLE NITRILE Latex-Free Exam Gloves...
Clear plastic sleeve envelopes a plastic suction catheter. Sleeve slides over exudate to reduce potential clinician contact....
Medicine Products: